Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9-Pragmatic Research and Innovation through Multinational Experimentation.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
23 Jan 2024
Historique:
received: 19 06 2023
accepted: 15 01 2024
medline: 24 1 2024
pubmed: 24 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

In an era focused on value-based healthcare, the quality of healthcare and resource allocation should be underpinned by empirical evidence. Pragmatic clinical trials (pRCTs) are essential in this endeavor, providing randomized controlled trial (RCT) insights that encapsulate real-world effects of interventions. The rising popularity of pRCTs can be attributed to their ability to mirror real-world practices, accommodate larger sample sizes, and provide cost advantages over traditional RCTs. By harmonizing efficacy with effectiveness, pRCTs assist decision-makers in prioritizing interventions that have a substantial public health impact and align with the tenets of value-based health care. An international network for pRCT provides several advantages, including larger and diverse patient populations, access to a broader range of healthcare settings, sharing knowledge and expertise, and overcoming ethical and regulatory barriers. The hypothesis and study design of pRCT answers the decision-maker's questions. pRCT compares clinically relevant alternative interventions, recruits participants from diverse practice settings, and collects data on various health outcomes. They are scarce because the medical products industry typically does not fund pRCT. Prioritizing these studies by expanding the infrastructure to conduct clinical research within the healthcare delivery system and increasing public and private funding for these studies will be necessary to facilitate pRCTs. These changes require more clinical and health policy decision-makers in clinical research priority setting, infrastructure development, and funding. This paper presents a comprehensive overview of pRCTs, emphasizing their importance in evidence-based medicine and the advantages of an international collaborative network for their execution. It details the development of PRIME-9, an international initiative across nine countries to advance pRCTs, and explores various statistical approaches for these trials. The paper underscores the need to overcome current challenges, such as funding limitations and infrastructural constraints, to leverage the full potential of pRCTs in optimizing healthcare quality and resource utilization.

Identifiants

pubmed: 38263138
doi: 10.1186/s13063-024-07935-y
pii: 10.1186/s13063-024-07935-y
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

80

Informations de copyright

© 2024. The Author(s).

Références

Lurie JD, Morgan TS. Pros and cons of pragmatic clinical trials. J Comp Eff Res. 2013;2(1):53–8.
doi: 10.2217/cer.12.74 pubmed: 24236521
Harrington J, Gouda P, Ezekowitz J, Mentz RJ. Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemp Clin Trials. 2022;113. Accessed 22 Jan 2024.
Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71–2.
doi: 10.1136/bmj.312.7023.71 pubmed: 8555924 pmcid: 2349778
Ioannidis JPA. Evidence-based medicine has been hijacked: a report to David Sackett. J Clin Epidemiol. 2016;73:82–6.
doi: 10.1016/j.jclinepi.2016.02.012 pubmed: 26934549
Barden J, Derry S, McQuay HJ, Moore AR. Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain. 2006;121(3):207.
doi: 10.1016/j.pain.2005.12.011 pubmed: 16495012
Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004;170(4):477–80.
pubmed: 14970094 pmcid: 332713
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;(2). Available from:  https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000033.pub3/full . Cited 2023 Apr 1.
Fröbert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. New Engl J Med. 2013;369(17):1587–97.
doi: 10.1056/NEJMoa1308789 pubmed: 23991656
Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. New Engl J Med. 2017;377(12):1132–42.
doi: 10.1056/NEJMoa1706443 pubmed: 28844201
Götberg M, Christiansen EH, Gudmundsdottir IJ, et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. New Engl J Med. 2017;376(19):1813–23.
doi: 10.1056/NEJMoa1616540 pubmed: 28317438
Hofmann R, James SK, Jernberg T, et al. Oxygen therapy in suspected acute myocardial infarction. New Engl J Med. 2017;377(13):1240–9.
doi: 10.1056/NEJMoa1706222 pubmed: 28844200
Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147.
doi: 10.1136/bmj.h2147 pubmed: 25956159
Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27–36.
doi: 10.1038/nrd1927 pubmed: 16485344
Jack Lee J, Chu CT. Bayesian clinical trials in action. Statist Med. 2012;31(25):2955–72.
doi: 10.1002/sim.5404
Diamond GA, Kaul S. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol. 2004;43(11):1929–39.
doi: 10.1016/j.jacc.2004.01.035 pubmed: 15172393
Gupta SK. Use of Bayesian statistics in drug development: Advantages and challenges. Int J Appl Basic Med Res. 2012;2(1):3–6.
doi: 10.4103/2229-516X.96789 pubmed: 23776799 pmcid: 3657986
Price K, LaVange L. Bayesian methods in medical product development and regulatory reviews. Pharm Stat. 2014;13(1):1–2.
doi: 10.1002/pst.1608 pubmed: 24408566
Rosner GL. Bayesian methods in regulatory science. Statistics in Biopharmaceutical Research. 2020;12(2):130–6.
doi: 10.1080/19466315.2019.1668843 pubmed: 32489520
Spiegelhalter. Bayesian approaches to clinical trials and health-care evaluation. 1st ed. Chichester; Hoboken, NJ: Wiley; 2004.
Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study Rationale and Design. Annals ATS. 2020;17(7):879–91.
doi: 10.1513/AnnalsATS.202003-192SD
Park JJH, Detry MA, Murthy S, Guyatt G, Mills EJ. How to use and interpret the results of a platform trial: users’ guide to the medical literature. JAMA. 2022;327(1):67–74.
doi: 10.1001/jama.2021.22507 pubmed: 34982138
Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian data analysis. 3rd ed. New York: Chapman and Hall/CRC; 2015.
Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian adaptive methods for clinical trials. Boca Raton: CRC Press; 2015.
Rajkumar CA, Foley MJ, Ahmed-Jushuf F, et al. A placebo-controlled trial of percutaneous coronary intervention for stable angina. N Engl J Med. 2023;0(0):null.
Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395–407.
doi: 10.1056/NEJMoa1915922 pubmed: 32227755 pmcid: 7263833
Lawler PR, Hochman JS, Zarychanski R. What are adaptive platform clinical trials and what role may they have in cardiovascular medicine? Circulation. 2022;145(9):629–32.
doi: 10.1161/CIRCULATIONAHA.121.058113 pubmed: 35226556
Pericàs JM, Derde LPG, Berry SM. Platform trials as the way forward in infectious disease’ clinical research: the case of coronavirus disease 2019. Clin Microbiol Infect. 2023;29(3):277–80.
doi: 10.1016/j.cmi.2022.11.022 pubmed: 36462745

Auteurs

Elmir Omerovic (E)

Department of Cardiology, Sahlgrenska University Hospital, Institute of Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Bruna Stråket 16, 41345, Gothenburg, Sweden. elmir@wlab.gu.se.

Mark Petrie (M)

British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK.

Björn Redfors (B)

Department of Cardiology, Sahlgrenska University Hospital, Institute of Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Bruna Stråket 16, 41345, Gothenburg, Sweden.

Stephen Fremes (S)

Department of Surgery, University of Toronto, Toronto, ON, Canada.
Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Sunnybrook Research Institute, Toronto, ON, Canada.

Gavin Murphy (G)

Cardiovascular Research Centre, University of Leicester, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK.

Guillaume Marquis-Gravel (G)

Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.

Alexandra Lansky (A)

Division of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

Eric Velazquez (E)

Division of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

Divaka Perera (D)

British Heart Foundation Centre of Research Excellence and National Institute for Health and Care Research Biomedical Research Centre at the School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, London, UK.

Christopher Reid (C)

Curtin School of Population Health, Faculty of Health Sciences, Curtin University, Kent Street, Bentley, WA, 6102, Australia.

Julian Smith (J)

Department of Surgery (School of Clinical Sciences at Monash Health), Monash University, Melbourne, VIC, Australia.
Department of Cardiothoracic Surgery, Monash Health, Melbourne, VIC, Australia.

Peter van der Meer (P)

Department of Cardiology, Center for Blistering Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Eric Lipsic (E)

Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, the Netherlands.

Peter Juni (P)

Oxford Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK.

John McMurray (J)

British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK.

Johann Bauersachs (J)

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Lars Køber (L)

Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Jean L Rouleau (JL)

Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Canada.

Torsten Doenst (T)

Department of Cardiothoracic Surgery, Friedrich-Schiller-University Jena, University Hospital, Jena, Germany.

Classifications MeSH